OKYO Pharma Ltd (OKYO) — research page
US · us-cm-kg/NASDAQ/OKYO · as of 2026-11-08
Identity and listing
OKYO Pharma Ltd is listed on NASDAQ under the ticker OKYO. Its ISIN is USG6724L1165. Its LEI is not on the record, because no GLEIF record carries the exact legal name in jurisdiction US. Its security type is recorded as non-operating entity type (other). Its segment is not on the record. Its sector is 2836 Biological Products, (No Diagnostic Substances). Its jurisdiction is not on the record. Its status is listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | OKYO Pharma Ltd | source · 2026-11-08 |
| exchange | NASDAQ | source · 2026-11-08 |
| ticker | OKYO | source · 2026-11-08 |
| ISIN | USG6724L1165 | source · 2026-10-05 |
| LEI | not on the record | |
| security type | Non-operating entity type (other) | source · 2026-11-08 |
| segment | not on the record | |
| sector | 2836 Biological Products, (No Diagnostic Substances) | source · 2026-11-08 |
| jurisdiction | not on the record | |
| status | listed, not halted | source · 2026-11-08 |
The disclosure read
The record holds 88 filings in the twelve months from 2025-11-08 to 2026-11-08, across 47 filing days. The filings comprise 28 directors' dealings, 4 prospectuses, 11 regulatory filings and 45 results. The median gap between filing days is 4.0 days. The latest filing is a results filing dated 2026-11-05, 3 days before the record date of 2026-11-08. The NASDAQ median cadence gap is 6.0 days across 4,359 issuers, and the NASDAQ median filings count is 52, with a median latency of 5.0 days. The sector median cadence gap is 5.5 days across 176 issuers, the sector median filings count is 65.5, and the sector median latency is 4.0 days.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 88 | 4 | 3 |
| exchange median: NASDAQ (4359 issuers) | 52 | 6 | 5 |
| sector median: 2836 Biological Products, (No Diagnostic Substances) (176 issuers) | 65.5 | 5.5 | 4 |
| date | type | category | filing |
|---|---|---|---|
| 2026-11-05 | results | 6-K | 6-K — 6-K |
| 2026-10-06 | results | 6-K | 6-K — 6-K |
| 2026-09-29 | results | 6-K | 6-K — 6-K |
| 2026-09-09 | results | 6-K | 6-K — 6-K |
| 2026-09-08 | results | 6-K | 6-K — 6-K |
window 2025-11-08 to 2026-11-08 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor of record is not on the record, because the latest annual report cover carries no dei:AuditorName tag. Its location is not on the record. The record holds no auditor changes.
Events and halts
The record holds no listing, delisting or name change lines. The domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The issuer is listed and not halted.
Orderability
The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.
rule acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
Six research houses are named on the issuer's investor-relations page: H.C Wainwright & CO, Lucid, Piper Sandler, B Riley, Goldman Research Company and Goldman Research.
| research house | analyst | source · read date |
|---|---|---|
| H.C Wainwright & CO | issuer page · 2026-11-11 | |
| Lucid | issuer page · 2026-11-11 | |
| Piper Sandler | issuer page · 2026-11-11 | |
| B Riley | issuer page · 2026-11-11 | |
| Goldman Research Company | issuer page · 2026-11-11 | |
| Goldman Research | issuer page · 2026-11-11 |
Open research
Six openly published research notes are on the record. Piper Sandler & Co. published notes dated 2026-08-01, 2026-07-01 and 2026-02-19. H.C. Wainwright & Co. published a note dated 2026-01-29. B. Riley Securities published a note dated 2025-12-08. Lucid Capital Markets published a note dated 2025-07-31.
| date | publisher | note | kind |
|---|---|---|---|
| 2026-08-01 | Piper Sandler & Co. | Mgmt Meeting Takeaways: Compelling Risk/Reward Setup; Execution in Focus | issuer-sponsored |
| 2026-07-01 | Piper Sandler & Co. | Recent Regulatory Update Provides Solid Path to Potential Value Creation | issuer-sponsored |
| 2026-02-19 | Piper Sandler & Co. | Can Urcosimod Offer Relief For NCP? | issuer-sponsored |
| 2026-01-29 | H.C. Wainwright & Co. | FDA Endorses Planned Phase 2b/3 Trial in Neuropathic Corneal Pain; Reiterate Buy | issuer-sponsored |
| 2025-12-08 | B. Riley Securities | OKYO Pharma Limited (OKYO – $1.91*) | issuer-sponsored |
| 2025-07-31 | Lucid Capital Markets | Developing a Novel Drug for Severe Eye Pain; Initiating with a Buy Rating and a $13 Price Target | issuer-sponsored |
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The vintage is sealed. The sealed years that hold the issuer are 2021, 2022, 2023, 2024, 2025 and 2026. The earliest sealed date of the market is 2021-01-04. The live record began on 2026-09-12.
Sources
14 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)
- 10.2
- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)
- 10.3
- https://data.sec.gov/submissions/CIK0001849296.json (identity.name)
- 10.4
- https://mcp.us-cm-kg.ai/events/NASDAQ/OKYO (the disclosure lines)
- 10.5
- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)
- 10.6
- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.7
- https://okyopharma.com/investors/analyst-coverage/ (coverage)
- 10.8
- https://okyopharma.com/wp-content/uploads/2026/08/Piper-Note-August-2026.pdf (open research)
- 10.9
- https://okyopharma.com/wp-content/uploads/2026/07/Piper-July-2026-Update.pdf (open research)
- 10.10
- https://okyopharma.com/wp-content/uploads/2026/02/OKYO-Piper-Report-Feb-26.pdf (open research)
- 10.11
- https://okyopharma.com/wp-content/uploads/2026/01/OKYO-HCW-FDA-Endorses-Planned-Phase-2b_3-Trial-in-Neuropathic-Corneal-Jan-26.pdf (open research)
- 10.12
- https://okyopharma.com/wp-content/uploads/2025/12/OKYO-B-RIley-Initiation-PT-5.pdf (open research)
- 10.13
- https://okyopharma.com/wp-content/uploads/2025/07/OKYO-Initiation-Report-by-Lucid-7-31-25.pdf (open research)
- 10.14
- https://mcp.us-cm-kg.ai/record/NASDAQ/OKYO (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"USG6724L1165"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:a2b937dae9e9667a.